2020 ANNUAL REPORT CONNECT. TABLE OF CONTENTS

LETTER TO MEMBERS 4 ADVOCATE. STRATEGIC PRIORITIES 5 THE LIFE SCIENCES CENTER 6

ADVOCACY 7

ADVANCE. STATE & FEDERAL POLICY COMMITTEES 8

LIFE SCIENCES PENNSYLVANIA PENNSYLVANIA LEGISLATURE 10

WWW.LIFESCIENCESPA.ORG PROGRAMS 12

PARTNERS 24

MEMBERSHIP 28

BOARD OF DIRECTORS 34

COMMITTEES 35

SPONSORS 36

2 3 A LETTER TO OUR MEMBERS CONNECT. ADVOCATE. ADVANCE. STRATEGIC PRIORITIES

he past year was filled with challenges, changes Added advocacy priorities: Tand calls to action. In many ways, 2020 was The Life Sciences PA team engaged in additional a test; a test of our organization’s perseverance, advocacy efforts that mirrored our COVID- ability to adapt, and determination to remain true 19-related communications efforts. While we to the core accountabilities of Life Sciences PA, were sharing information on government- VISION regardless of circumstance. mandated business closures, we were working simultaneously on behalf of our membership We are all acutely aware of the challenges to advocate for the criteria used to determine Facilitate partnerships between and among Pennsylvania is considered the most attractive presented in 2020, and I was proud to see our essential businesses, the importance and impact location in the United States for establishing a industry come together in ways that may not of upstream suppliers, and criticality of business Ensure a supportive business and public policy entrepreneurs, large industry, small companies, have been possible without the difficulties the continuity for life sciences organizations. 1 2 research institutions and funding organizations life sciences organization by life sciences leaders coronavirus pandemic presented. climate in Pennsylvania to support company within the U.S. and by those outside the U.S. We’ve come out of this year with a stronger formation and retention in the Commonwealth. to advance company formation, innovation, job seeking to establish U.S. operations. As an organization, Life Sciences PA shifted to dedication to our mission, stronger relationships handle the challenges of the year, but never failed and a stronger sense of the value of our community. creation and success in the industry. to keep our membership as our primary focus and priority. Despite the challenges, the adjustments, This report takes a look at specific facts and figures, the unpredictability - 2020 was not all bad news. and also provides a broader, more holistic look at how Life Sciences PA is advocating on behalf This year’s challenges presented several positive of the industry and advancing the life sciences in MISSION opportunities: Pennsylvania. New and enhanced partnerships: The pandemic may have shifted how we work, but Promote and support strategic engagement Support efforts to position Pennsylvania as a top Life Sciences PA was pleased to strengthen never changed why we work, which is for you, 3 between the Pennsylvania life sciences industry 4 location for life sciences business and opportunity Life Sciences Pennsylvania’s mission is to ensure many existing partnerships and facilitate several our Members. Thank you to all of our Members new partnerships, such as our collaboration who contributed to the accomplishments of 2020. Pennsylvania is the United States hub for the life and key industry stakeholders. through select communication initiatives. with The Pennsylvania Department of Health, Our Members are the reason we were able to find sciences by creating a business and public policy The Hospital and Healthsystem Association of meaning, grow as an organization, and discover environment which fosters life sciences growth Pennsylvania, and The Pennsylvania Chamber new avenues of support over the past year. of Business and Industry in the call for medical and success. supplies and expertise. As the new year is underway, it is clear 2020 sharpened our focus. We move into 2021 with Unexpected avenues to provide support: new partnerships, new friendships, new growth, Throughout 2020, Life Sciences PA shared and a refreshed sense of optimism. timely state and federal updates that affected Provide valued services and access to cost- our Members. Additionally, Life Sciences PA We appreciate your continued support and look provided information and resources on financial forward to 2021 as we continue to connect, 5 efficient resources for Association members opportunities, calls for personal protective advocate and advance - now more than ever. to make informed decisions and grow their equipment (PPE), and relief packages. Another critical area of support was related to Life CHRISTOPHER P. MOLINEAUX businesses. Sciences PA’s dissemination of reopening PRESIDENT & CEO updates relevant to our Member organizations.

4 55 THE LIFE 2020 ADVOCACY COMMITTEE SCIENCES ADVOCACY JULIAN RITCHEY, SANOFI (CHAIR) TERRI LEE TAYLOR, MERCK & CO., INC. CENTER SUCCESSES BRYANT LIM, IDERA PHARMACEUTICALS CHRIS MOLINEAUX, LIFE SCIENCES PA

or the early months in 2020, the Life Sciences Center RITA NORTON, AMERISOURCEBERGEN he year began with typical advocacy activity as Life Sciences PA served as a hub for Life Sciences PA Members. With BRUCE SHOOK, F held a ‘Meet and Greet’ in Washington, D.C. with Congressman VESPER MEDICAL, INC. reservable rooms and collaborative spaces, the Center was a T Guy Reschenthaler and had meetings with seven congressional space where Members could focus on work, mingle with other members and offices to thank them for their work to permanently for programs important to our Members. In a challenging Life Sciences PA members, and host team or group meetings. repeal the Medical Device tax at the end of 2019. Life Sciences PA state budget environment, we were pleased to see funding In response to the outbreak of COVID-19, Life Sciences PA also brought the industry's voice to two hearings at the state level maintained – via two separate budget bills – for our allies at announced in March that the Center would be temporarily closed until it was once again safe to reopen. While the Life Sciences PA team – one focused on Association Health Plans and the other on drug the Life Sciences Greenhouses and the Ben Franklin Technology was disappointed to miss the daily in-person interaction with Members at the Center, the health and safety of our Members and the Life pricing. Partners. Support for the Research & Development Tax Credit Sciences PA team was the primary focus and the main reason for the temporary closure. In mid-March, however, the coronavirus pandemic upended and the Keystone Innovation Zones was also maintained. We were also pleased to see the NIH budget increased for the sixth After closing the Center, the Life Sciences PA team quickly set out to find a way to re-create the collaborative, community-focused feel of our 2020 advocacy strategy. We quickly adjusted to ensure consecutive year. the Center, only through a virtual, socially distanced medium. In mid-March, Life Sciences PA was pleased to share the creation of the our Members were kept up to date and informed on actionable Virtual LSPA Community, an online forum where Members can post updates, share digital business cards, and message other Members. guidance from public officials in Harrisburg and Washington, Finally, we were proud to see the Pennsylvania House and Senate The Virtual LSPA Community is a safe way for Members to network and ensures open lines of communication between members of the D.C. Our response also became proactive as we set up legislative unanimously pass Senate Bill (SB) 983, the Newborn Child Virtual LSPA Community. As of December 31, 2020, there are 442 Members in the Virtual LSPA Community. briefings and webinars about the tireless efforts of our Member Testing Act, providing further testing and follow-up treatment for companies to develop diagnostics, and therapeutics to Pennsylvania newborns. In a challenging year, this was a positive While the Virtual LSPA Community has been a great alternative to in-person interaction and networking, the Life Sciences PA team is combat COVID-19. development for many of our patient advocacy group Members. eager to see the Center reopen when it is once again safe to do so. Even as our work shifted to a virtual setting – Advocacy Days were Life Sciences PA will continue to work diligently to educate and held virtually over a three-day period with nearly 70 participants inform our elected officials on the Commonwealth’s life sciences 2020 and 32 virtual meetings – Life Sciences PA continued to advocate ecosystem and the important work it is leading in 2021. COVID-19 FEB FEB 28 MAR MAR 11 MAR 11 MAR 13 Life Sciences PA releases educational resource regarding the broad The World Health Organization For the safety of all Members Janssen enters a collaboration with the and sweeping efforts of Pennsylvania-based companies engaged in (WHO) declares the and staff, Life Sciences PA Beth Israel Deaconess Medical Center to MILESTONES combating the coronavirus in advance of the pandemic declaration. SARS-CoV-2 outbreak announces the temporary closure support the development of a preventive a global pandemic. of the Center. candidate for COVID-19.

6 7 Life Sciences PA hosts Congresswoman Chrissy Life Sciences Pennsylvania hosts a roundtable with Houlahan (D06) at Fujirebio Diagnostics in Representative Kerry Benninghoff (R-Centre/Mifflin), Life Sciences PA hosts Meet and Greet with Chester County, strengthening Life Sciences PA’s House Majority Whip, and a handful of western Congressman Guy Reschenthaler (R-14). Pennsylvania Member companies. Life Sciences ongoing advocacy efforts. Pennsylvania’s JAN 27 FEB 20 MAR 9 President & CEO, Chris Following the Life Sciences PA Life Sciences PA, with Molineaux, testifies repeal of the submits written Takeda Pharmaceuticals, at an informational Medical Device testimony focused Life Sciences PA participates in a dinner with hearing before Tax, Life Sciences on the importance participates in the the Japanese Ambassador to the House Insurance PA meets with of investment in drug AdvaMed Fly-In, an the United States, Shinsuke Committee about members of the development and annual event focused Sugiyama, a nod to the the importance of Pennsylvania innovation for the on the public policy importance of the business providing an affordable delegation who Pennsylvania House priorities that are and cultural relationships health insurance option were instrumental Health Committee important to our shared between Japan to Pennsylvania’s small in our repeal informational hearing medical device and and the Commonwealth of Pittsburgh - Rep. Kerry Benninghoff with Tory Moore, Ariel innovation firms. Washington, D.C. – Congressman Guy Reschenthaler efforts. Malvern, PA – Fujirebio Diagnostics President and CEO, on drug pricing. diagnostic membership. Pennsylvania. Precision Medicine, Suma Krishnan and Kate Romano, Krystal speaks with members of the Life Sciences PA Federal Monte Wiltse (left) provides Congresswoman Chrissy Biotech, Christian Manders, Promethean Life Sciences and Josh JAN 21 Policy Committee JAN 28 Houlahan (right) a tour of their facility FEB 25 FEB 25 & 26 MAR 3 Suskin, Krystal Biotech

2020 ADVOCACY ACTIVITY

ACTIVITY RESULTING FROM COVID-19

MAR 31... EARLY APRIL Life Sciences PA hosts a multi-state congressional briefing with state association partners from Life Sciences around the country to educate congressional members and staff on the life sciences community PA joins the PA response to COVID-19. Speakers include Rick Bright, Director, BARDA; Kate Broderick, Senior Business Reopening Vice President, R&D Pharmaceuticals and nCoV Project Lead, Inovio; Rick Nettles, Vice Coalition. President, U.S. Medical Affairs, Janssen Infectious Diseases; and Josh Trotta, Senior Director, Business Development Clinical Enablement, Thermo Fisher Scientific.

8 9 Life Sciences PA works with state association partners to host a multi-state congressional briefing Life Sciences PA hosts the first virtual “meet focused on Research and Development Amid a Pandemic. Speakers at the event included Dr. Life Sciences PA and greet” held with Congressman John Kelsey Martin, Dean, David Geffen School of Medicine, UCLA; Dr. Jeff Castelli, Chief Development continues to advocate for Joyce, M.D. (PA-13) who has a unique Officer, Amicus Therapeutics; Dr. Michael Dudley, President and CEO at QPEX Biopharma; Dr. David our priorities, including view on healthcare policy. Fajgenbaum, Co-Founder and Executive Director, Castleman Disease Collaborative Network. The Pennsylvania Association Health MAY 21 Legislature Plans, the Research and JUL 7 passes a five- Development Tax Credit, month stop-gap Life Sciences PA hosts the Keystone Innovation budget in late Advocacy Days, Zone Tax Credit and the Life Sciences May, and Life during which nearly Ben Franklin Technology The President signs federal budget and rare PA provides Sciences PA 70 Life Sciences PA Partners to be fully pediatric disease priority review voucher, which Congresswoman advocated for Members participated funded for the remaining ensures short-term extension of the Rare Pediatric Chrissy Houlahan and secured in 32 virtual meetings seven-month budget after Disease Priority Review Voucher (PRV) program (D-PA) a forum state advocacy with members of Governor signs included in this funding package. Life Sciences PA to speak with priorities the Pennsylvania a five-month budget continues to work with Senator Casey to incentivize Members included that Legislature over a funding state operations the research and development of novel medicines Congressman John Joyce provides an overview of in her district. budget. three-day period. through November 2020. for children with rare disorders. current affairs in Washington, D.C. Dr. David Fajgenbaum provides an overview of how rare disease patients MAY 1 MAY 29 MAY 27, 28 & 29 JUN 30 have been affected by the COVID-19 pandemic. OCT 1

2020 ADVOCACY ACTIVITY

ACTIVITY RESULTING FROM COVID-19

APR 24 MAY 29 JUL 28 AUG 6 SEP 21 Life Sciences PA organizes a Senator Casey and Congressman As part of a coalition of The President signs an executive Life Sciences PA legislative briefing for all members Kelly donate plasma, an important statewide associations, order on the Defense Production testifies at the of the State Legislature as well as component of several COVID-19 Life Sciences PA signs Act (DPA) and Life Sciences PA Pennsylvania House the members of the Pennsylvania therapies in development by Life on to a letter urging commits to monitoring its effect, Democratic Policy Congressional delegation to inform Sciences PA Members. Senator Toomey to especially in the short-term, Committee hearing Stephen Tang of OraSure Technologies provided an Clockwise from top left: Jonathan Steckbeck, Representative them on what Members are doing to overview of testing and its role in COVID-19 both co-sponsor the SAFE TO on the robust global supply on COVID-19’s Mark Longietti (D-7) (hearing room), Shawn Patrick O’Brien, combat COVID-19. during and after heavy mitigation. WORK Act (S. 4317). chains upon which many of our Impact on Innovation. Rep. Mary Jo Daley and Christopher Molineaux. Member companies rely.

10 11 Q4 2020 FEDERAL ADVOCACY UPDATES

ELECTION RECAP MEDICARE COVERAGE OF Amid a hectic year, the 2020 presidential election was held November 3. The saying “elections have consequences” is especially INNOVATIVE TECHNOLOGY (MCIT) true for the life sciences community, which is influenced significantly by the decisions of policy makers at the federal and state levels In response to a proposed rule on the Medicare Coverage of Innovative Technology (MCIT), Life Sciences PA crafted a letter – signed of government. Pennsylvania was, once again, a battleground state and played a pivotal role in the outcome of the presidential by 21 medical technology Members – expressing our collective support for the rule. The rule would create a new reimbursement election. pathway for certain new medical devices. A copy of the letter addressed to Center for Medicare and Medicaid Services (CMS) In addition to the presidential election, voters cast their ballots for: Administrator Seema Verma can be found here.

• All 18 Pennsylvania representatives in the U.S. House of Representatives This new pathway would allow for Medicare coverage of medical devices that receive the “breakthrough” designation by the • Three statewide offices (Attorney General, Treasurer and Auditor General) U.S. Food and Drug Administration (FDA) on the same day they are given FDA market authorization. Qualifying devices would be covered under MCIT for four years. This would provide medical device manufacturers time to build evidence on the value of their • 25 of the 50 Pennsylvania Senators new technology. • All 203 Pennsylvania House members

To provide Members up-to-date information on the election results, Life Sciences PA hosted a “2020 Election Results” page on its website, which served as a resource for election updates and results. After ballots were cast, all 18 Pennsylvania congressional COVID-RELIEF/FEDERAL SPENDING PACKAGE The U.S. House and Senate passed an omnibus spending bill and COVID-relief package December 21. The total legislative package members were reelected and Republicans won two statewide races: Treasurer and Auditor General. Republicans also maintained comprised approximately $2.3 trillion in federal spending, with the omnibus spending bill accounting for $1.4 trillion and the their majority in the Pennsylvania House and Senate. COVID-relief package accounting for $900 billion. President Trump signed the spending bills on December 27, 2020. BIOBREAKFAST WITH U.S. SENATOR TOOMEY The two packages fund or extend several policies important to Life Sciences PA Members. The packages would make additional Paycheck Protection Program (PPP) assistance available, provide the NIH a budget of $49.2 billion (a $1.25 billion increase from AND CONGRESSMAN DOYLE FY2020) and extend the Rare Pediatric Priority Review Voucher (PRV) program by four years. Life Sciences PA was disappointed to In a busy election year, Life Sciences PA was pleased to partner with Christian Manders, Chief Operating Officer of Promethean see the legislation did not include temporary liability protection for our Members following directives and guidelines, Lifescience, Inc. and the Pittsburgh BioBreakfast to host two separate conversations featuring U.S. Senator Pat Toomey and U.S. but understands it will be a priority in future relief package negotiations. Congressman Mike Doyle. The conversations were held October 8 and October 19, respectively. Both discussions afforded Pittsburgh- based life sciences leaders the opportunity to hear directly from members of the Pennsylvania Congressional Delegation and update those legislators on new developments occurring in southwestern Pennsylvania’s life sciences ecosystem.

2020 COVID-19 MILESTONES

MAR MAR 9 MAR 13 MAR 13 MAR 13 MAR 20 MAR 21 Integral Molecular announces The President officially declares the Life Sciences PA launches the The Food and Drug Administration (FDA) Life Sciences PA joins The Pennsylvania The University of Pennsylvania opens the mobilization of two of its key coronavirus outbreak an emergency Virtual LSPA Community, an grants Roche Emergency Use Authorization Department of Health, The Hospital & Philadelphia’s first drive-thru coronavirus technology platforms to aid in disaster. online networking tool designed for its high-volume coronavirus diagnostic Healthsystem Association of Pennsylvania, testing site. the discovery of vaccines and to facilitate strategic connections within 24 hours of receiving the and The Pennsylvania Chamber of Business therapeutics against the novel between our Members. application. and Industry in the call for medical supplies coronavirus which causes COVID-19. and expertise.

12 13 Q4 2020 FEDERAL ADVOCACY UPDATES

ANTIMICROBIAL RESISTANCE (AMR) POLICY UPDATE DRUG PRICING UPDATE The Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms is a bill that would help incentivize the development The Trump Administration continued to move ahead with several proposals on “lowering the cost of prescription medicines.” Chief of novel antimicrobial resistant medicines. It removes a reimbursement barrier that disincentivizes hospitals and physicians from among these proposals is the interim final rule on its Most Favored Nation (MFN) policy. The Administration provided more details utilizing new antibiotics even when they may be the most appropriate treatment for a patient. Given some COVID-19 patients suffer November 20 about how this flawed policy would be implemented, and Life Sciences PA remains opposed to its overarching goal of from secondary bacterial infections, and the ever-evolving threat of antimicrobial resistance, policy support is urgently needed to simply importing foreign price controls on medicines in the United States. Life Sciences PA has significant concerns about how this prevent a public health crisis. policy will inhibit investment in breakthrough therapies and cures, ultimately limiting patient access to innovative medicines.

Life Sciences PA organized a series of meetings with members of the Pennsylvania congressional delegation and Member companies The MFN model will peg the price of 50 ‘sole-source’ medicines in Medicare Part B to the reimbursement rates at the lowest adjusted focused on the antimicrobial space to urge those members to support the DISARM Act and include it in any forthcoming legislative price from 22 economically similar countries. The list of the 50 medicines initially affected by this rule can be found on page 50 of package. Life Sciences PA is pleased that Pennsylvania currently has more co-sponsors for this legislation than any other state and this document. thanks Senator Casey for his efforts as the Democrat lead in the U.S. Senate. Life Sciences PA sent this letter to the entire Pennsylvania delegation expressing the concerns of the Most Favored Nation policy. Additionally, Life Sciences PA is supportive of another bill on the AMR front – the Pioneering Antimicrobial Subscriptions to End Life Sciences PA will be working with its national partners and the Pennsylvania congressional delegation to oppose the Trump Upsurging Resistance (PASTEUR) Act. This legislation would modify current reimbursement methods and employ a subscription-like Administration efforts on this rule, and will also be submitting comments to the Administration on this policy. This Trump administration model for government payments to companies developing antimicrobials, helping to ensure some financial certainty for companies policy was halted by two court rulings. However, Life Sciences PA still plans to submit comments in opposition to this proposal and assuming the risk of developing these novel medicines. It would also utilize a grant program to promote appropriate stewardship of will be monitoring activities by the Biden Administration and Congress, which could seek to implement something similar in 2021. antibiotics and help hospitals report antibiotic use and resistance to the CDC. Life Sciences PA thanks Congressman Mike Doyle (PA- 18) for leading the introduction of this bill in the U.S. House of Representatives, and looks forward to building upon the momentum garnered by both DISARM and PASTEUR in the coming session of Congress. RARE PEDIATRIC PRIORITY REVIEW VOUCHER (PRV) Life Sciences PA was very pleased to see the four-year extension of the Rare Pediatric PRV program included in the COVID-relief/ omnibus spending bill. This extension provides certainty to our Members focused on developing medicines for children with rare disorders. Life Sciences PA is appreciative of Senator Casey’s leadership on this bill and its reauthorization. We will continue to push for a permanent extension of this program that is critical to incentivizing the research and development of novel therapies and cures Life Sciences Pennsylvania AMR members meet with Congressman Reschenthaler’s office: (clockwise from top left) Jonathan Steckbeck, Peptilogics; Kurt Imhof, LSPA; for rare disorders. Joe Larsen, Venatorx; Ted Schroeder, Nabriva; Evan Loh, Paratek; Steve Sandor, Paratek; Liz Barton, Cong. Reschenthaler’s office. 2020 COVID-19 MILESTONES

MAR MAR 21 APR APR 1 APR 3 To address the shortage of personal protective equipment (PPE) within hospitals and Actuated Medical, Inc. repurposes USciences faculty and staff collect other care facilities, Eric Sugalski, President and CEO of Archimedic creates the its manufacturing facility to produce and donate more than 69,000 Origami Respirator using a vacuum cleaning bag, rubber bands, and a zip tie. face shields for first responders and pieces of PPE including gloves, N95 medical professionals battling the masks, protective suits, and more to coronavirus pandemic. healthcare institutions in Philadelphia.

14 15 Q4 2020 STATE ADVOCACY UPDATES

PENNSYLVANIA LEGISLATURE PASSES PENNSYLVANIA EXPANDS NEWBORN SCREENINGS SEVEN-MONTH BUDGET Governor Tom Wolf signed into law Act 133, The Newborn Child Testing Act, in late November providing further testing and follow- up treatment for Pennsylvania newborns. Senate Bill (SB) 983 passed unanimously in both legislative chambers just days prior to The Pennsylvania Legislature passed a five-month stop-gap budget in late May due to uncertainty around the Commonwealth of receiving the Governor’s signature. Pennsylvania’s fiscal situation amid a global pandemic. The Legislature passed and the Governor signed in November 2020 a series of bills comprising a seven-month budget funding the Commonwealth of Pennsylvania through June 30, 2021. Sponsored by Senator John DiSanto (Dauphin & Perry Counties), SB 983 requires all babies born in Pennsylvania be screened for all conditions listed on the federal Recommended Uniform Screening Panel (RUSP). The RUSP is a list of 35 core and 26 secondary The budget provides seven of 12 months of level funding to the following budget programs important to Life Sciences PA and its conditions for which every baby is recommended to be screened after birth, with each tested condition carrying follow-up treatment. members: Prior to SB 983, Pennsylvania tested babies for up to 38 conditions, consisting of a mandatory panel of 10 screenings and a • Ben Franklin Technology Partners - $8.458 million for the remaining seven months (bringing the yearly total to $14.5 million) supplemental panel of 28 screenings. SB 983 ensures Pennsylvania babies be screened for 61 or more conditions. • Department of Health Bio-Technology Research - $4.492 million for the remaining seven months (bringing the yearly The bill also creates a Newborn Screening Account within the Department of Health where a Newborn Screening Fee will be billed total to $7.7 million) to health providers and submitted to insurance for payment. • The Life Sciences Greenhouses ($3 million) and the Commonwealth Universal Research Enhancement (CURE) Program are funded Due to the tireless work of the Patient Advocacy Groups, babies born in Pennsylvania will forever reap the benefits of the testing that through the Tobacco Settlement Fund, and were fully funded for 12 months in the budget passed in May. will now provide early detection for treatable diseases. The expansion of newborn screenings in Pennsylvania has been a priority for • Research and Development Tax Credits ($55 million) and Keystone Innovation Zones ($15 million) remain fully funded Life Sciences PA and we are thrilled with the passage of this important legislation. In an uncertain budget year, Life Sciences PA is pleased to see its budget priorities maintain level funding and thanks the State Policy Committee for its concerted effort to ensure these critical programs remain intact.

2020 COVID-19 MILESTONES

APR APR 6 APR 9 APR 9 APR 9 APR 14 Life Sciences PA contributes to the creation of the Christian Manders, COO at Promethean LifeSciences Inc. announces it has found a leading CSL Behring and Takeda join forces to Sanofi and GSK announce they are joining Pennsylvania Manufacturing Call to Action Portal, designed and Director on LSPA’s Board taps Life Sciences PA for a experimental drug candidate against develop a treatment for COVID-19. forces to create a COVID-19 vaccine and to foster the connections businesses need to get critical networking connection that results in the delivery of 500 SARS-CoV-2 and plans to test the drug in hope to start testing the vaccine in humans COVID-19-related products to market or retrofit their pairs of ski goggles to front-line workers in New York City the following months. in the second half of 2020. operations to begin production of those products. in need of PPE.

16 17 Q4 2020 STATE ADVOCACY UPDATES

GOVERNOR TOM WOLF VETOES COVID-19 LIABILITY PATIENT SUMMIT PROTECTION FOR BUSINESS Life Sciences PA was proud to host its inaugural Patient Summit November 12. This virtual half-day event provided our patient advocacy group members and public officials an intimate forum to learn about exciting developments in the life sciences ecosystem Life Sciences PA is a member of a broad coalition of business, nonprofit, education, and healthcare organizations supportive of and better understand the interaction between payers, patients, innovators and policy makers. The Summit kicked off with an temporary, targeted legislation that would provide legal safe harbor for organizations operating in good faith and complying with Opening Keynote from David Fajgenbaum, a rare disease patient with Castleman Disease who is also a scientist at the University relevant requirements that protect employees from the spread of COVID-19. Accordingly, and in partnership with this coalition, Life of Pennsylvania working tirelessly to develop a cure for his own rare disease. He has been featured at other Life Sciences PA events Sciences PA signed-on to letters sent to the Governor and the General Assembly expressing our support for House Bill (HB) 1737. and is a remarkable, and inspirational, speaker. This bill appropriately provided our member organizations legal safe harbor to prevent opportunistic plaintiff’s attorneys from filing liability lawsuits under the guise of COVID protections. Life Sciences PA was disappointed to see Governor Wolf veto HB 1737. The Summit concluded with a presentation by retiring Pennsylvania State Representative Marcy Toepel, Chair of the Rare Disease Caucus in the Pennsylvania House, and the sponsor of the legislation that created the Rare Disease Advisory Council in the commonwealth – Life Sciences PA Member companies have been working tirelessly to develop diagnostics, therapeutics and vaccines to fight the at the time one of only four in the country. After she presented on the best ways patient groups can interact with and get the attention COVID-19 pandemic. As these scientists and researchers are working in difficult conditions while adhering to extensive mitigation of legislators, the day concluded with a legislator/patient group networking session on . measures to ensure patients have expeditious access to these life-saving medical innovations, they should be protected from predatory litigation. The Summit was well attended by members of our patient group, public officials and/or their staff, and colleagues from Member companies who enjoyed presentations on how insurance benefit design affects out-of-pocket costs for patients, how companies and HB 1737 did not provide complete immunity, and entities covered by this legislation would still be liable for acts considered careless, patient groups can successfully partner, and the exciting, but lengthy developments in the treatment of sickle cell disease. Summit reckless or deliberately wrongful. However, the legislation did ensure businesses, institutions, and organizations following public registrants represented 21 patient groups and 22 legislators and/or their staff at both the state and federal level. Life Sciences PA health guidance issued by the state and/or federal governments would be granted basic protections against frivolous lawsuits. thanks Amicus Therapeutics, Harmony Biosciences, , Novartis and We Work for Health PA for sponsoring this event, and thanks Merck for their help in securing our speaker on insurance benefit design.

In 2012, Dr. Fajgenbaum co-founded the Castleman Disease Representative Marcy Toepel presented at the Summit The Summit’s attendees included Collaborative Network (CDCN), a global initiative dedicated and discussed how patient groups can attract the representatives from patient groups, to accelerating research and treatment for Castleman disease attention of legislators. legislators, and Life Sciences PA (CD) to improve survival for all patients with CD. Members. 2020 COVID-19 MILESTONES

APR APR 15 APR 15 APR 16 APR 18 Temple University Hospital starts the first clinical trial in the announces the launch of its third Inovio Pharmaceuticals secures a $6.9M Life Sciences PA supports its economic development partners United States testing an experimental therapy known as COVID-19 test, a lab-based serology blood test for the grant to fund a clinical trial for its at the Valley Forge Tourism & Convention Board (VFTCB), who gimsilumab as a potential coronavirus treatment. detection of the antibody, IgG, that identifies if a person has coronavirus vaccine. launched a #MontCoStrong t-shirt fundraiser to help support had the novel coronavirus (COVID-19). Montgomery County’s COVID-19 Response Fund.

18 19 STATE POLICY COMMITTEE FEDERAL POLICY COMMITTEE

DANIEL AMBURN, UCB EVAN FACHER, UNIVERSITY HANNAH KRANZ, STEVE SANDOR, PARATEK DORCAS ADEKUNLE, ABBVIE TONY GIBSON, UNIVERSITY CHOL PAK, THERMO FISHER OF PITTSBURGH BUCHANAN INGERSOLL & PHARMACEUTICALS OF PITTSBURGH SCIENTIFIC DOMENICK ARGENTO ROONEY JEREMY ALLEN, SPARK (CHAIR), MERCK DAVID FORDE, UNIVERSITY BARBARA SCHILBERG, THERAPEUTICS PETER GROLLMAN, CHOP ARTHUR-PAUL PETROSINELLI, OF THE SCIENCES KATHRYN LAVRIHA, SANOFI BIOADVANCE ORGANOGENESIS MARC ARNOLD, LIVANOVA BILL ANDRESEN, UNIVERSITY PAUL HOWARD, AMICUS JOE GARBA, ALEXION CHARLES LEITGEB, BAYER DAVID SMITH, TROUTMAN OF PENNSYLVANIA THERAPEUTICS AMY REDL, SANOFI (CHAIR) SAUL BEHAR, PHILADELPHIA PHARMACEUTICALS INC. PEPPER CITY SCIENCE CENTER TIMOTHY LYDEN, ELI LILLY GRANT BARBOSA, KATIE JONES, ALEXION KATIE NASH, UNIVERSITY TONY GREEN, BEN FRANKLIN SAM SPEAKER, KPMG EMERGENT BIOSOLUTIONS; CITY SCIENCE CENTER BRENDAN BENNER, MDMA TECHNOLOGY PARTNERS CATE MCCANLESS, JACQUELINE KIRBY, JAZZ OF SOUTHEASTERN HARMONY BIOSCIENCES JENNIFER EVANS STACEY, MICHAEL BARNARD, PHARMACEUTICALS DEBBIE TEKAVEC, CARNEGIE MEL BILLINGSLEY, LIFE PENNSYLVANIA THE WISTAR INSTITUTE JOHNSON & JOHNSON MELLON UNIVERSITY SCIENCES GREENHOUSE OF TIM MCNULTY, CARNEGIE CHRIS KOVOLSKI, CENTRAL PENNSYLVANIA DENNIS GROSS, MELLON UNIVERSITY TIMOTHY SULLIVAN, SAUL BEHAR, UNIVERSITY VILLANOVA UNIVERSITY KRISTEN MOLLOY, PENN PENNSYLVANIA DRUG GLAXOSMITHKLINE CITY SCIENCE CENTER MEDICINE BEN CHANDHOK, BIO DISCOVERY INSTITUTE JEANNIE MORRIS, LEHIGH SARAH KYLE, ELI LILLY UNIVERSITY MONA THINAVONGSA, TED BUCKLEY, BRAEBURN JOHN VERSAGGI, LIVANOVA STEVEN COBB, UNIVERSITY ETHAN HASBROUCH, SMITH & NEPHEW PHARMACEUTICALS JOE LARSEN, VENATORX OF PENNSYLVANIA CHRISTINA MUNOZ, PAUL SELTMAN, SMITH & AMERISOURCEBERGEN KARL UHLENDORF, ASTELLAS PAULA BURG, PFIZER BRYAN LEWIS, KIDNEY NEPHEW PATRICK COLLINS, CSL JOHN HOHENWARTER, CANCER ACTION NETWORK BEHRING NOVARTIS KATIE NASH, UNIVERSITY KARLA WHITE, CSL BEHRING CHRIS CARTER, LEHIGH (KCAN) PETE STEHOUWER, BAYER CITY SCIENCE CENTER UNIVERSITY LOUISE CONLON, KURT IMHOF, LIFE SCIENCES DAVID WILSON, DREXEL CATE MCCANLESS, PHIL THEVENET, GSK IMMUNOCORE PENNSYLVANIA TODD NYQUIST, LONG, UNIVERSITY PATRICK COLLINS, CSL HARMONY BIOSCIENCES NYQUIST & ASSOCIATES BEHRING STEVE SANDOR, PARATEK KIMBERLY DAVIS, JOHNSON MICHELLE JACQUIS, VERTEX JOE MCGOWAN, NOVARTIS PHARMACEUTICALS & JOHNSON PHARMACEUTICALS MARK O'ROURKE, TAKEDA JULIE DIETRICH, WEST CHESTER UNIVERSITY GREG MONTANARO, DREXEL TERRI BOOKER, SICK CELLS AMY DEMPSTER, BRIAN KENNEDY, KEVIN ORR, PFIZER UNIVERSITY PITTSBURGH TECHNOLOGY KRISTIN DINI, TEMPLE LIZ SCHWARTZ, MERCK COUNCIL AMY PRENTICE, UNIVERSITY RITA NORTON, PATRICK DENTINGER, ASTRAZENECA AMERISOURCEBERGEN ABSORPTION SYSTEMS JACQUELINE KIRBY, JAZZ CHELSEY FIX, GBS-CIDP PHARMACEUTICALS JOY RUSSELL, GENENTECH JULIE DIETRICH, WEST CHESTER UNIVERSITY

2020 COVID-19 MILESTONES

MAY MAY 4 MAY 9 MAY 22 MAY 29 The FDA grants Roche emergency use authorization (EUA) Life Sciences PA and 12 Member companies are featured in Life Sciences PA launches the COVID-19 Resource Page to Rockland Immunochemicals Inc. develops a critical antibody for its antibody blood test that gauges people’s exposure a Philadelphia Magazine article written by Queen Muse on provide resources and guidance on employee and customer reagent essential to antibody tests used to determine SARS-CoV-2 and immune response to COVID-19. the global need for cutting-edge medicine. well-being, the allocation of PPE and supplies, and the exposure for patients suspected to have contracted COVID-19. reopening of businesses.

20 21 PENNSYLVANIA LEGISLATURE PENNSYLVANIA LEGISLATURE ENGAGEMENT LIFE SCIENCE CAUCUS CO-CHAIRS RARE DISEASE CAUCUS

he Rare Disease Caucus works to educate and advocate on behalf of individuals with rare diseases. A rare disease is a disease or condition that T affects fewer than 200,000 people in the United States. One in 12 Pennsylvanians is living with a rare disorder. The Rare Disease Caucus works closely with the Rare Disease Advisory Council, comprised of patients, public officials, and organizations researching therapies and cures for rare diseases, and is dedicated to improving the quality of life for patients in Pennsylvania with rare diseases. Pennsylvania is one of eight states in the United States with a Rare Disease Advisory Council.

REP. TIM REP. VALERIE REP. MARK REP. DAVID SEN. ANDY SEN. BOB BRIGGS GAYDOS LONGIETTI ZIMMERMAN DINNIMAN MENSCH

(D-MONTGOMERY (R-ALLEGHENY (D-MERCER (R-LANCASTER (D-CHESTER (R-BERKS, COUNTY) COUNTY) COUNTY) COUNTY) COUNTY) BUCKS AND MONTGOMERY COUNTIES)

2020 PUBLIC AFFAIRS SERIES SPONSORS RARE DISEASE CAUCUS CO-CHAIRS

REP. MARK REP. MARCY SEN. JOHN BLAKE SEN. JUDY WARD LONGIETTI TOEPEL (D-LACKAWANNA, (R-BLAIR, CUMBERLAND, (D-MERCER (R-MONTGOMERY LUZERNE AND MONROE FRANKLIN, FULTON AND COUNTY) COUNTY) COUNTIES) HUNTINGDON COUNTIES) 2020 COVID-19 MILESTONES

JUL JUL 10 JUL 10 SEP SEP 14 SEP 23 The first COVID-19 patient in Germany is successfully treated Temple University Hospital treats the first U.S. patients in a Researchers at the University of Pittsburgh School of Johnson & Johnson announces it’s with novel Diaphragm Therapy from Lungpacer Medical, Inc. COVID-19 immunotherapy clinical trial. Medicine identify a biological molecule - previously 60,000-subject phase 3 assessment used to create the Ab8 drug - that could be used to of its single-dose COVID-19 vaccine neutralize the SARS-CoV-2 virus causing COVID-19 is underway. in mice and hamsters.

22 23 PROGRAMS

espite the changes and unpredictability, in 2020, Life Sciences PA was able to adjust plans, S.A.V.E. ROUNDTABLE The Life Sciences PA Membership team hosted a S.A.V.E. Roundtable networking event for partners in the group purchasing program. Comprised of a diverse MAY 14, 2020 group of organizations that offer various products and services, Life Sciences PA’s S.A.V.E. Group Purchasing Program is a business network offering exclusive adapt to our environment, and provide valuable programming to our Members. In March, D HOSTED VIRTUALLY discounts on products and services to Life Sciences PA Members. The roundtable was hosted exclusively as an opportunity for S.A.V.E. providers to learn more Life Sciences PA quickly transitioned to hosting events through a virtual platform to ensure the about each other and the far-reaching impact of the program.

safety of our Members. By shifting to hosting virtual events, Life Sciences PA was able to maintain C SUITE EVENT Life Sciences PA’s C Suite Event welcomed C-level executives to hear from Severin Schwan, CEO of Roche Group and Jeffrey Marrazzo, CEO of Spark our diverse calendar of programs and host 24 programs throughout 2020, 21 of which were MAY 20, 2020 Therapeutics as they provided an in-depth look at Roche’s acquisition of Spark. Attendees were provided the unique opportunity to ask questions and interact HOSTED VIRTUALLY with Jeff and Severin, who discussed all aspects of the acquisition and provided a behind-the-scenes look at the highly anticipated deal. hosted virtually. Events ranged from workshops, leadership panels, and educational events to our large Life Sciences Future conferences and Annual Awards Program. Our virtual programs LIFE SCIENCES In June 2020, Life Sciences PA issued a statement in response to America's renewed, intense focus on racial injustice and inequality. As we stated in PA’S DIVERSITY & that message, there are no simple answers or expedient solutions to address longstanding racism and systemic inequities afflicting our country. We also provided attendees the opportunity to connect with one another, learn from colleagues and INCLUSION INITIATIVE acknowledged that it is not the nature of Pennsylvania’s life sciences community to sit by idly while these problems persist. Our Members work every day with 2020 PROGRAM JUNE 2020 industry leaders, and find support from other members of the life sciences community. passion, empathy and perseverance to find solutions to the most complex medical problems afflicting patients of all races, nationalities, and backgrounds. In an effort to promote access to Life Sciences PA’s programming, we began our Diversity & Inclusion Initiative in July by offering complimentary student OVERVIEW registrations to Life Sciences PA events. In order to share this offer with as many students as possible, we conducted outreach to the colleges and universities in our membership, to Historically Black Colleges and Universities, and to partner organizations to help spread the word.

LIFE SCIENCES FUTURE - Hundreds of viewers gathered virtually from July 15-17 for Life Sciences Future – MedTech, a three-day conference focused on timely topics and updates CONNECT@ AVE More than 80 guests gathered in Malvern for Life Sciences PA’s first Connect@ 24(3 IN PERSON / 21 VIRTUAL) MEDTECH related to the medical device, diagnostic, and digital health communities, as well as all related stakeholders. Presenters showcased new scientific advancements JANUARY 29, 2020 event of the year, held at AVE Malvern. Guests networked over cocktails and hors TOTAL PROGRAMS JULY 15-17, 2020 while looking ahead at the future of the industry. MALVERN, PA d’oeuvres in a relaxed atmosphere while touring the AVE apartment complex and HOSTED VIRTUALLY learning about their fellow Member’s space and associated amenities. ANNUAL AWARDS Ahead of the public premiere of the 2020 Annual Awards Program, Life Sciences PA hosted a virtual VIP Reception that featured a preview of the documentary- BREAKFAST Life Sciences PA hosted a Breakfast Leadership Panel focused on medical 104 PROGRAM VIP RECEPTION style program. The group of honorees, members of the Life Sciences PA Board of Directors, the Life Sciences PA team, and colleagues from sponsoring LEADERSHIP PANEL cannabis. Panelists included Armando Anido, Chairman & Chief Executive SPEAKERS JULY 27, 2020 organizations tuned in for the early reveal of the hour-long program. FEBRUARY 12, 2020 Officer at Zynerba Pharmaceuticals, Howard Goodwin, Partner at Intrinsic HOSTED VIRTUALLY KING OF PRUSSIA, PA Capital Partners, and Eric Marsh, Child Neurologist at Children’s Hospital of Philadelphia (CHOP), as well as Robert J. “BJ” Clark, Litigation Partner at Ballard 2020 ANNUAL Life Sciences PA’s 2020 Annual Awards Program premiered at 4:00 p.m. July 29, 2020. The documentary-style production focused on the successes of 1,296 AWARDS PROGRAM 2019, heroes of COVID-19, the current unrest in our country and, of course, the lifetime achievement of some of our community’s leaders. In order to share Spahr LLP, who served as moderator. COMPANIES REPRESENTED JULY 29, 2020 the tremendous successes and accomplishments with the largest audience possible, Life Sciences PA was pleased to share this production broadly on the Life VIRTUAL PREMIERE Sciences PA website for anyone and everyone who was interested in viewing. BUILDING YOUR LSPA Toward the end of February, Life Sciences PA hosted a Building Your LSPA Planning for the 2020 Annual Awards Program began back in 2019 at a time when Life Sciences PA hoped to host the event in person - as usual - with dinner NETWORK Network event in @LSPA – The Life Sciences Center. Attendees shared information and awards. However, as plans changed in March, the program was shifted to a virtual platform. As the virtual event did not allow us to serve dinner as part FEBRUARY 28, 2020 about themselves, their organizations, and how they are hoping to use their Life 4,039 INDIVIDUALS REGISTERED of the program, Life Sciences PA asked those who had already purchased a ticket to consider donating the proceeds from their seat or table purchase to the WAYNE, PA Sciences PA membership. Philadelphia chapter of Life Science Cares. As a result of our community’s generosity, $176,000 was donated to Life Sciences Cares Philadelphia. Life Sciences PA would like to share our additional thanks to those who selflessly contributed to our local community at a time when it was needed most. BUILDING YOUR LSPA New Life Sciences PA Members from across the state of Pennsylvania were invited NETWORK to participate in the Building Your LSPA Network event. Event participants dialed 1,133 BASICS OF BIOTECH Basics of Biotech was a comprehensive, virtual course comprised of half-day sessions from August 17-21 focused on the development of biopharmaceuticals. MAY 14, 2020 in from across Pennsylvania, Delaware, New Jersey and Ohio, representing ON-DEMAND VIEWS AUGUST 17-21, 2020 The course was curated for those who may be new to the or pharmaceutical industry, those looking for a high-level understanding of drug HOSTED VIRTUALLY biotechnology, pharmaceutical, investment, construction, medical device, and HOSTED VIRTUALLY development, or those wanting a refresher on the development process. recruitment organizations. BUILDING YOUR All new Life Sciences PA Members are encouraged to attend the Building Your LSPA Network event to jump start their immersion into the Life Sciences PA 137 LSPA NETWORK community. At this program, Life Sciences PA’s new Members learned about the S.A.V.E. group purchasing program, Life Sciences PA programs planned for the EDUCATIONAL SESSIONS SEPTEMBER 1, 2020 remainder of 2020, and how to best immerse themselves in the Life Sciences PA community to get the most of their membership. 2020 COVID-19 MILESTONES HOSTED VIRTUALLY

OCT OCT 12 OCT 26 OCT 30 AstraZeneca receives $486M in U.S. funding to Life Sciences PA calls on community members to sign on Life Sciences PA informs Members of the importance of the flu shot advance COVID-19 antibody treatment into two phase-III to a letter that supports the Administration’s proposed for the health and safety of our community. clinical trials. rule, Medicare Coverage of Innovative Technology and Definition of Reasonable and Necessary, which is another important step in advancing the development of life saving innovations.

24 25

556 27 289 TOTAL REGISTRANTS S TATES + D.C ., CANADA, UNIQUE OR G A N I Z ATIO N S ISRAEL, ZIMBABWE REPRESENTED and SOUTH AFRICA T I T L FEATURED SPEAKERS B Y E E S E D AMBASSADOR DEBORAH L. BIRX, MD N E White House Coronavirus Response Coordinator T 30% T

Keynote Speaker - Fireside Chat A 27%

LUIS JODAR, MD 18% Chief Medical Officer for Vaccines Medical Development 25% and Medical/Scientific Affairs, Pfizer 556 27 289 Closing Speaker TOTAL REGISTRANTS CEO/PRESIDENT/VPS TATES + D.STUDENTC ., CANADA, UNIQUE OR G A N I Z ATIO N S ISRAEL, ZIMBABWE REPRESENTED OTHER DAVID B. NASH, MD, MBA DIRECTOR/MANAGERand SOUTH AFRICA Founding Dean Emeritus at Jefferson College of Y T I T L E Population Health, Thomas Jefferson UniversityFEATURED SPEAKERS B E S R E A K D O W E Keynote Speaker - Fireside Chat B N D AMBASSADOR DEBORAH L.E BIRX, MD N E E D White House Coronavirus Response Coordinator T 30% N T JANET WOODCOCK, MD E Keynote Speaker - Fireside Chat A T 27% PROGRAMS IN Q4 Director, Center for Drug Evaluation and Research (CDER), T Food and Drug Administration (FDA) A LUIS JODAR, MD 51% 49% 28918% Keynote Speaker - Fireside Chat 556 27 Chief Medical Officer for Vaccines Medical Development TOTAL REGISTRANTS S TATES + D.C ., CANADA, UNIQUE OR G A N I Z ATIO N S 25% and Medical/Scientific Affairs, Pfizer LIFE SCIENCES FUTURE - BIOPHARM ISRAEL, ZIMBABWE REPRESENTED Closing Speaker and SOUTH AFRICA September 30 - October 2, 2020 | Hosted virtually CEO/PRESIDENT/VP STUDENT FEATURED SPEAKERS B Y T I T L E 556 2754 53289 149DAVID B. NASH, MD, MBA S DIRECTOR/MANAGER OTHER E DIVERSITY & INCLUSION R&D COMPANIES E undreds of viewers gathered virtually from September 30 - October 2 for Life Sciences Future – BioPharm, a three-day conference focused on TOTAL REGISTRANTS S TATES + D.C .,RESE CANADA,A RCH UNIQUESPEA ORKGERA NSI Z ATIO N S Founding Dean Emeritus at Jefferson College of D AMBASSADOR DEBORAH L. BIRX, MD SERVICE PROVIDERS N ISRAEL, ZIMBABWEINSTI TUT I ONS REPRESENTED STUDENTSPopulation Health, Thomas Jefferson University E White House Coronavirus Response Coordinator T 30% A K D O timely topics and updates related to the biotechnology and pharmaceutical communities, and all related stakeholders. Presenters showcased and SOUTH AFRICA T E W Keynote Speaker - Fireside Chat B R N H A Keynote Speaker - Fireside Chat G E T I T L - I D G 27%E FEATURED SPEAKERS B Y N D E B Y E E L F E N T B Y A E E new scientific advancements while looking ahead at the future of the industry. Life Sciences Future – BioPharm featured well-known speakers including: S R S S I F D E E E I E S E E E C N JANET WOODCOCK,A MD E E D D LUIS D JODAR, MD D AMBASSADOR DEBORAH L. BIRX, MD T 16% 18% T N N N Director, CenterI for Drug EvaluationN and Research (CDER), T E E ChiefE Medical OfficerO for Vaccines MedicalE Development 289 A 556 27 25% , M.D. , MD, MBA White House Coronavirus Response Coordinator T 289289 AMBASSADOR DEBORAH L. BIRX IAN L. VALERIO, M.D., M.S., M.B.A., FACS, DAVID B. NASH T 289 T 55655627556 2727 T 18% N TOTAL REGISTRANTS S TATES + D.C ., CANADA, UNIQUE OR G A N I Z48.8%ATIO N S 30% Food and Drug Administration (FDA) T T andT Medical/Scientific Affairs, PfizerT TOTAL REGISTRANTSTOTAL REGISTRANTS S TATES +TOTAL D.C ., REGISTRANTS CANADA, S TAUNIQUETESS TA TES+OR GD.+A D.NCICZ.,.,ATI CANADA, OCANADA,N S UNIQUE OR GUNIQUEA N I Z ATIO N S OR G A N19I Z%ATI O N S ISRAEL, ZIMBABWE REPRESENTED White House Coronavirus Response Commander (CDR), Medical Corps, U.S. Navy, Founding Dean Emeritus at Jefferson College A A A 49% Keynote Speaker - Fireside Chat 289 A 51% 556 27 27% and SOUTH AFRICA ISRAEL, ZIMBABWE ISRAELREPRESENTEDISRAEL, ZIMBABWE, ZIMBABWE KeynoteREPRESENTED SpeakerREPRESENTED - Fireside Chat 18% Coordinator Plastic and Reconstructive Surgeon at Harvard of Population Health, Thomas Jefferson 556TOTAL REGISTRANTS 27S TATES + D.C .,289 CANADA, UNIQUE OR G A N I Z ATIOClosingN S Speaker and SOUTH AFRICAY T I T L E and289 andSOUTH SOUTH AFRICAAFRICA 10% STUDENT 556FEATURED SPEAKERS 27 B CEO/PRESIDENT/VP

TOTAL REGISTRANTS S TATES + D.C ., CANADA,ISRAEL, ZIMBABWEUNIQUEE OS R G A N I Z ATIO N S REPRESENTED E 70% Medical School and Massachusetts General University TOTAL REGISTRANTS ISRAELS TATES, ZIMBABWE + D. C ., CANADA,DREPRESENTED UNIQUE OR G A TNI TILZ ATIO N S T I T L T I T L LUIS JODAR,AMBASSADORFEATURED MDFEATURED DEBORAH SPEAKERS L. BIRX, MDSPEAKERSFEATUREDand SOUTH SPEAKERS AFRICA B Y E B Y E B Y E and SOUTH AFRICA N 18%S DAVID B. NASH, MD,S MBA S DIRECTOR/MANAGER OTHER DR. LUIS JODAR E E E E 21% White House Coronavirus Response Coordinator T Hospital Chief Medical Officer for Vaccines MedicalISRAEL, ZIMBABWE Development30 % T I T L E REPRESENTEDE E E T Y I T 26% FEATURED SPEAKERS 50.9%B T L E FEATURED SPEAKERS S D B Y D D A 25% Chief Medical Officer for Vaccines Medical Keynote SpeakerAMBASSADOR - Fireside Chat DEBORAHAMBASSADOR L.DEBORAHE BIRX,27% L. BIRX,MD MDS Founding Dean Emeritus at Jefferson College of AMBASSADOR DEBORAH L. andBIRX, SOUTH MD AFRICAE N N 2% N D E and Medical/ScientificAMBASSADOR DEBORAH Affairs, L. BIRX, Pfizer MD E E E E N 0.3% White House CoronavirusWhite House CoronavirusResponse Response Coordinator Coordinator Population Health,T Thomas JeffersonT University Development and Medical/Scientific Affairs, JANET WOODCOCK White House Coronavirus Response Coordinator E T D 30% 54 30% 30% 149 White House Coronavirus Response Coordinator T 53 LUIS JODAR, MD AMBASSADOR DEBORAH L. BIRX, MD 18%30 % T T I T L T T R&D COMPANIES FEATUREDClosing Speaker SPEAKERS T N B Y E A K D O A E A A Chief KeynoteMedicalKeynoteKeynote Officer Speaker Speaker for -Vaccines Fireside - Speaker FiresideMedical Chat Development ChatKeynote - Fireside Speaker -25% ChatFireside27% Chat A S 27%Keynote SpeakerRESEA RC - HFireside 27% ChatSPEA K ERS 27%DIVERSITY & INCLUSIONR E W White House Coronavirus Response Coordinator T Pfizer Director, Center for Drug Evaluation and and Medical/Scientific Affairs, Pfizer CEO/PRESIDENT/VP30E % WHITE (EUROPE/MID.STUDENT HISPANIC/LATINO/ B N FEMALE T E 18-24 35-44STUDENTS55+ E SERVICE PROVIDERS ClosingKeynoteLUIS Speaker JODAR, Speaker MD - Fireside Chat 18% A D EAST/N. AFRICA) INSTISPANISHTUTI ONS E Research (CDER) at the Food and Drug 27% D AMBASSADORDAVID B. NASH,LUISChief LUIS DEBORAHJODAR,Medical MD, Officer JODAR, MDMBA for L.Vaccines BIRX, Medical MD MD DevelopmentLUIS JODAR, CEO/PRESIDENT/VP MD STUDENT DIRECTOR/MANAGERN OTHER MALE 25% 18% ASIAN AMERICAN18% INDIAN/ 18%25-34 45-54 N and Medical/Scientific Affairs, Pfizer DIRECTOR/MANAGER OTHER E Administration (FDA) DAVID B. NASH,Chief MD, MBAMedical OfficerChief Medicalfor Vaccines Officer for Vaccines Medical Medical Development DevelopmentJANET WOODCOCK, MD E WhiteFounding House DeanChief Coronavirus Emeritus Medical Officer at Response Jefferson for Vaccines Coordinator College Medical of Development T 30% ALASKA FoundingLUISClosing Dean JODAR, EmeritusSpeaker atMD Jefferson College of TRANSGENDER 25% 25% 25% T CEO/PRESIDENT/VP STUDENT T 18% BLACK/AFRICANDirector, Center for YDrug G E N DEvaluation and Research (CDER),L F - I D E N A G E T Y Populationand Health,andMedical/Scientific Thomas Medical/Scientific Jefferson Affairs,University Pfizerand Medical/Scientific Affairs, PfizerAffairs, Pfizer NATIVE B E E T B Chief Medical Officer for Vaccines Medical Development A R S I KeynotePopulation Speaker Health, -Thomas Fireside Jefferson Chat University DIRECTOR/MANAGER OTHER AMERICAN S F S DAVID B. NASH, MD, MBA K 27% A R E A D O W 25% E E I E KeynoteClosing SpeakerClosing Speaker - Fireside ChatSpeaker Closing Speaker B N K DFood and Drug AdministrationE (FDA) E C Throughout the conference, attendees tuned in to virtual sessions, joined Zoom networking sessions and participated in one-on-one video partnering meetings. andFounding Medical/Scientific Dean Emeritus at Jefferson Affairs, College Pfizer of E E A O W A E Keynote Speaker - Fireside Chat E CEO/PRESIDENT/VPB R STUDENT D CEO/PRESIDENT/VP CEO/PRESIDENT/VPSTUDENT D STUDENT D Population Health, Thomas Jefferson University D N T 51% 49% 16% JANETClosing WOODCOCK, Speaker MD N E A K D O W E Keynote SpeakerN - Fireside Chat N I N Keynote Speaker - Fireside Chat E B R N E DIRECTOR/MANAGERDIRECTOR/MANAGEROTHER OTHER O LUIS JODAR, MD T DIRECTOR/MANAGER OTHER E E Director,DAVID CenterDAVID B. for NASH,Drug Evaluation B. MD, NASH, andMBA Research (CDER), DAVIDMD, B. MBA NASH,E MD, MBA CEO/PRESIDENT/VP18% STUDENT E T E D T T 18% N T D A 48.8% Food and DrugFounding Administration (FDA) Dean EmeritusFounding Dean at EmeritusJefferson at Jefferson College College of T T Chief MedicalFoundingJANET Officer WOODCOCK, Dean for Emeritus MDVaccines at JeffersonMedical College Development of N REVER S E PITCNH E S T JANET WOODCOCK, MD E DIRECTOR/MANAGER OTHER 19% DAVID B. NASH, MD, MBA E 51%T 49% 25% KeynoteDirector, Speaker Center - Fireside for Drug Chat Evaluation and Research (CDER), A A A PopulationPopulation Health, Thomas Health, JeffersonPopulation Thomas University Health, T Jefferson Thomas Jefferson University TUniversity 18% and Medical/ScientificFounding Dean Affairs, Emeritus Pfizerat Jefferson College of A Director, CenterFood and for Drug Drug Administration Evaluation (FDA) and Research 8(CDER), T K D K D E A K D O E A O W E A O W KeynoteKeynote Speaker - SpeakerFireside ChatKeynote - Fireside Speaker51% - ChatFireside49% Chat R W B R N B R N 10% PopulationKeynote Speaker Health, - Fireside Thomas Chat Jefferson University A B N ClosingFood and Speaker Drug Administration (FDA) E E E E A K D O E E 70% Keynote Speaker - Fireside Chat CEO/PRESIDENT/VPD R E W STUDENT D D 51% B 54N49% 149 N N 53 N Keynote54 SpeakerJANET -53 Fireside WOODCOCK, Chat149 JANET WOODCOCK,MD MD E R&D COMPANIES 21% JANET WOODCOCK, MD R&D COMPANIES RESEA RCH DIVERSITY & INCLUSION E E E 50.9% E 26% SPEAK ERS T D RESEA RCOTHERH T T DIVERSITY & INCLUSION DAVID B. NASH,Director, MD, MBA Center forDirector, Drug Center Evaluation forSERVICE Drug PROVIDERS Evaluation andDIRECTOR/MANAGER and Research Research (CDER), (CDER), SPEAK ERS Director,54 Center for Drug Evaluation149 and Research (CDER), T T T 53 STUDENTS N INSTI JANETTUTI ONS WOODCOCK, MD R&D COMPANIES 2% SERVICE PROVIDERS DIVERSITY & INCLUSION E A A RESEA RCH SPEAK ERS A STUDENTS FoodFood and Drug and Administration Drug Administration (FDA)Food and Drug Administration (FDA) (FDA)T INSTI TUTI ONS 0.3% Founding DeanDirector,INST EmeritusI TUTI ON CenterS at for Jefferson Drug EvaluationSTUDENTS College and ofResearch (CDER),SERVICE PROVIDERS G E - I D G T B Y N D E E L F E N T B Y A E 51% 49% 51% 49% 51% 49% KeynoteS KeynoteR Speaker - SpeakerFireside S ChatI F Keynote - Fireside SpeakerS - ChatFireside Chat A Population Health,FoodE and ThomasDrug Administration JeffersonE (FDA)UniversityI C E E G E N E F - I D E A E A G WHITE (EUROPE/MID. HISPANIC/LATINO/ D B Y D E D E L N T D B Y E S R S T I F S 16% 51% A49%K D O FEMALE 18-24 35-44 55+ N KeynoteE Speaker - FiresideN E Chat I I C N E E W G E N F - I D E A G E O R EAST/N. AFRICA)N SPANISH E E E E E E Y D L Keynote Speaker - Fireside Chat A B N B E E T B Y T D T D T D 48.8% 18% N T 16% R S I T T F 54 N N 149I T N S S 53 E 19% E E O E E MALE E ASIAN I AMERICAN INDIAN/ 25-34 45-54 A R&D COMPANIES A E A E C T T T 48.8% 18% N 18% E E E T T DIVERSITY &T INCLUSION RESEA RCH SPEAK ERS 10% 19% D D A ALASKA A D A A D 18% N TRANSGENDER BLACK/AFRICAN T 16% JANET WOODCOCK, MD 70% SERVICE PROVIDERSN N I NATIVE N STUDENTS10% 149E149 5454 5453149 53 O INSTI TUTI ONS 53 E 21% E R&D COMPANIES R&D COMPANIES E 50.9% 70% 26% T R&D COMPANIES AMERICAN T T RESERESEA RCH A RCH RESEDIVERSITYA RCH & INCLUSION DIVERSITYDIVERSITY & INCLUSION& INCLUSION 18% N T Director, Center for Drug EvaluationSPEAK ER Sand 2%ResearchSPEA K (CDER),ERSPEAS21% K ERS T 48.8% 26% T 50.9% T 54 0.3% 149 T 53 SERVICE PROVIDERS SERVICE PROVIDERS SERVICE PROVIDERS 19% STUDENTS2% STUDENTSA STUDENTSR&D COMPANIES INSTI TUTI ONS INSTI TUTI ONS A A Food and DrugRESEINST AdministrationIATUTRCHI ON S0.3% (FDA) DIVERSITY & INCLUSION A G E N WHITESPEA (EUROPE/MID.K ER S HISPANIC/LATINO/F - I D E A G 18% Y FEMALED E L N 18-24 35-44 55+ SERVICEY PROVIDERSE B E R EAST/N.WHITE AFRICA) (EUROPE/MID.SPANISH HISPANIC/LATINO/S STUDENTST I 51% B 49% FEMALE 18-24 35-44 55+ 10% KeynoteS SpeakerINSTI TUT -I ONFiresideS EAST/ChatN. AFRICA) F S E MALE ASIAN G E AMERICANE SPANISH INDIAN/ G E 25-34I C 45-54 E --II DD E MALEY G E N D Y ASIAN N D ALASKAE AMERICAN INDIAN/YL F - I DNE ND 25-34 45-54 L FL F A G E NE N REVEY A G ER S E PITCH E SY A G E TRANSGENDER B E B E BE ET A S EESBEY T I T I B B 70% D S S R BLACK/AFRICAN RNATIVED ALASKA S S RI F DS F F S S E TRANSGENDERE BLACK/AFRICAN EE TI E E I I E E Terri Lee Taylor, Vice President of State Government Affairs & Policy at Merck and Rachael Bushey (right), Partner and Chair of the Health Sciences Department at E AMERICAN NATIVEE C E EE 16%C C E E N E Y G E N D AMERICAN N E L F - I D E N I A NE A G E A A 8 21% D B D E DD E T O D DD B Y D D E S R E S I F T E S 16% T 50.9%T 16% 16% 26% T N E N T NN E I I N NN I I N N 18% C N T E O O Chairman of Life Sciences PA’s Board of Directors served as the moderator for Troutman Pepper and a member of Life Sciences PA’s Board of Directors prepared 48.8%E E E EE E O E EE E E E 2% T T A T T T T T T D T D T D 18%18% N N T T REVER S E PITCH E S 48.8% 48.8%18% T N 19% 48.8% T T REVET R S E PITCH E S T T 0.3% T T 16% T T A A N N I NA 19% 19% 19% O 8 E A A E A A 18% E A A Dr. Birx’s Fireside Chat. for her role as moderator of the Fireside Chat with Janet Woodcock. Karen DeLone A 8 A A 18% 18% T T 18% T 48.8% 18% N 54 T 53 149T 10% T 10% 19%R&D COMPANIES10%10% WHITE (EUROPE/MID. HISPANIC/LATINO/ (left), Senior Vice President & Chief Operating Officer of Life Sciences PA, assistedRESE A RCH A DIVERSITY70%A & INCLUSION A 18% FEMALE 18-24 35-44 55+ SPEAK ERS 70% 10% 70%70% EAST/N. AFRICA) SPANISH Rachael in her preparations while wearing a mask to promote health and safety. INSTI TUT50.9%I ONS 50.9% 50.9% STUDENTS70%50.9% 26%26%SERVICE 21% 21% PROVIDERS MALE 26% 21% ASIAN26% 21%AMERICAN INDIAN/ 25-34 45-54 2% 2% 2% ALASKA 0.3% 0.3%2% 21% TRANSGENDER BLACK/AFRICAN 50.9%0.3% 0.3% 26% NATIVE E I D 2% AMERICAN Y G N D 0.3% WHITE (EUROPE/MID.L F - E N HISPANIC/LATINO/WHITE (EUROPE/MID.WHITE (EUROPE/MID.Y A GHISPANIC/LATINO/E HISPANIC/LATINO/ B E R FEMALE FEMALE S E FEMALET I 18-24 B 35-44 55+ 18-24 35-44 18-2455+ 35-44 55+ 2020 COVID-19 MILESTONES S WHITE (EUROPE/MID.EAST/ N. AFRICA) HISPANIC/LATINO/F I SPANISHEAST/N. EAST/AFRICA)N. AFRICA)S SPANISHSPANISH E FEMALE E C E 55+ E MALE MALE WHITEASIANE (EUROPE/MID.MALE HISPANIC/LATINO/AMERICANA ASIAN INDIAN/ ASIAN 18-24E AMERICAN35-44AMERICAN INDIAN/ INDIAN/25-34 45-54 25-34 45-54 D FEMALE EAST/N. AFRICA)D SPANISH 25-3418-24D 45-5435-44 55+ EAST/N. AFRICA) SPANISHALASKAT 16%ALASKAALASKA N MALE TRANSGENDERTRANSGENDERASIAN BLACK/AFRICANN TRANSGENDER AMERICANI BLACK/AFRICAN INDIAN/ BLACK/AFRICANN 25-34 45-54 E MALE EASIAN NATIVEAMERICANO INDIAN/ E25-34 45-54NATIVENATIVE REVER S E PITCH E S T T AMERICAN AMERICANAMERICAN ALASKAALASKAN T TRANSGENDER48.8% TRANSGENDER 18% T BLACK/AFRICANT BLACK/AFRICAN NATIVENATIVE T 19% 8

NOV 9 NOV 23 A DEC A 11 A DEC 12 NOV DEC AMERICANAMERICAN 18% 10% Pfizer cites early data showing its coronavirus vaccine Merck acquires OncoImmune for its COVID-19 treatment REVE8R S E PITCREVETheH EFDAS R issuesS70%E PITCthe8 firstREVEH emergencyE RSS E PITC useH E Sauthorization (EUA) Distribution of the Pfizer-BioNTech vaccine begins as doses reduces the risk of COVID-19 illness by more than 90%. CD24Fc in a $425M deal. 8 REVER S E PITCforH aE Svaccine to the Pfizer-BioNTech COVID-19 vaccine for 21% are packed for delivery to hospitals around the country. 50.9%REVER 8S E PITCH E S 26% 8 0.3% the prevention of COVID-19 in 2%individuals 16 years of age and older. WHITE (EUROPE/MID. HISPANIC/LATINO/ FEMALE 18-24 35-44 55+ EAST/N. AFRICA) SPANISH MALE ASIAN AMERICAN INDIAN/ 25-34 45-54 ALASKA TRANSGENDER BLACK/AFRICAN NATIVE 26 AMERICAN 27 8 REVER S E PITCH E S PROGRAMS IN Q4

TELL ME ABOUT YOUR JOB ife Sciences PA thanks the generous series sponsors who are dedicated to making a positive difference in the lives of underrepresented groups. Bi-Weekly Series | Hosted virtually L ife Sciences PA was pleased to present the premiere of Tell Me About Your Job Wednesday, October 21. Tell Me About Your Job is a series TELL ME ABOUT YOUR JOB SPONSORS L of 30-minute, live online programs geared toward students. Hosted on a bi-weekly basis, the series features individuals from underrepresented groups who highlight their career path, explain their roles and associated responsibilities, and answer questions to help audiences learn more about the opportunities within the life sciences industry. The discussions are followed by a 30-minute Zoom networking session where attendees can foster connections with students, speakers, and other industry professionals.

DR. GEORGE (TREY) TYMISSHA JACKSON, NAJAH ELLISON HILTON JACKSON THORNE MS, RAC

Director of Product Director of Regulatory Associate Director Reimbursement Manager Development at Fujirebio Affairs at Castle Creek R&D Finance, Paratek at Neuronetics, Inc. Diagnostics Inc. Biosciences

DENISE (DEEDEE) DEMAN, (MODERATOR) Founder, Chairman & CEO of Bench International and Founder of The Forum of Global Pharmaceutical Diversity & Inclusion

2020 COVID-19 MILESTONES

DEC 15 DEC 18 The Wistar Institute, INOVIO Pharmaceuticals, Inc., AstraZeneca The U.S. Food and Drug Administration issues an emergency use and the Perelman School of Medicine at the University of authorization (EUA) for the second vaccine for the prevention of Pennsylvania are among a group of recipients of a $37.6M coronavirus disease 2019 (COVID-19) caused by severe acute award over two years for rapid preclinical development and respiratory syndrome coronavirus 2 (SARS-CoV-2). translational studies of DNA-encoded monoclonal antibodies (DMAbs) as countermeasures for COVID-19.

28 29 PROGRAMS IN Q4

BASICS OF BIOTECH CLINICAL TRIALS SUMMIT November 17-20, 2020 | Hosted virtually November 20, 2020 | Hosted virtually

asics of Biotech was a comprehensive, virtual course comprised of he Clinical Trials Summit (formally the CRO/CMO Summit) was B half-day sessions from November 17-20 focused on the development T held virtually November 20 using Life Sciences PA’s robust web- of biopharmaceuticals. The course was curated for those who may be based platform. Attendees tuned in to hear leaders in the field discuss new to the biotechnology or pharmaceutical industry, those looking for the future of clinical trials. Paul Duprex, PhD from the University of a high-level understanding of drug development, or those who wanted Pittsburgh opened the event as the keynote speaker discussing vaccines a refresher on the development process. Basics of Biotech was designed and the landscape of COVID-19 trials. The conversation continued for anyone interested in learning more about the development process as panelists Judy O’Grady and Ronni Fuchs from Troutman Pepper and required no prerequisite knowledge of the industry. Additionally, discussed hot legal topics surrounding clinical trials today. The half- this course was of value to those who support any step within the day Summit concluded with a panel of leaders who discussed the best development process of pharmaceuticals, including outside vendors. ways to strategize, plan and execute a clinical trial. Panelists included JeanMarie Markham shared insight on executing successful clinical trials in the midst of COVID-19. Takashi Asah of CMIC Group, Fran DeGrazio of West Pharmaceutical The course began with foundational basics and gave a detailed Services, JeanMarie Markham, RN, CCRA, of Clinlogix, Earl Sands, MD overview of the process from drug discovery to commercialization. of Parexel International Clinical Research, and Kristine Koontz, PhD(c), Attendees learned about the science behind biotech products, MBA, of GlaxoSmithKline. the clinical research process, regulatory filings, and scale-up for manufacturing. Additionally, the course covered the timely topic of COVID-19 vaccines. Attendees were able to earn up to 12 Continuing Legal Education credits upon completion of the live course, and up to six CLE credits for on-demand completion.

Paul Duprex, PhD provided an update on clinical trials related to COVID-19.

30 31 PROGRAMS IN Q4

BUILDING YOUR LSPA NETWORK SCRUB YOUR DECK December 10, 2020 | Hosted virtually December 10, 2020 | Hosted virtually

ll new Life Sciences PA Members are encouraged to attend n our current environment, digital presentations are daily occurrences A Building Your LSPA Network to jump start their immersion into the I and it has never been more important to effectively relay your skillset and Life Sciences PA community. In early December, new Members from knowledge base through a digital medium. Life Sciences PA’s Scrub Your across the state of Pennsylvania joined this virtual event to learn about Deck event was designed to help Members enhance their presentation their Life Sciences PA membership, meet some of their peers, and begin in investment pitches. Eleven emerging companies participated in our networking. Chris Molineaux, President & CEO of Life Sciences PA, virtual “Expert Studios” and received valuable coaching, counseling, opened the event with an overview of Life Sciences PA and its mission. He and feedback needed to make a successful funding pitch to advance also explained how any discipline that touches the life sciences industry their companies in 2021 and beyond. The day began with investors and is represented within Life Sciences PA’s membership. Leading the event corporate business development leaders discussing their insights on how and facilitating the discussion were Tom Hess, Senior Vice President start-up companies can successfully pitch to investors in a digital world. Scrub Your Deck kicked off with a panel featuring investors and corporate business development professionals who discussed the and CFO of Genomind, and Charlie Huntington, Managing Director- Speakers included: best strategies to pivot company pitches to digital and shared Investment Officer at Huntington Kraus Financial Group of Wells Fargo insight on how to invest in successful digital relationships. ANJALI KUMAR, PHD JON SKINNER Advisors. Tom and Charlie explained how the Life Sciences PA network Johnson & Johnson Innovation Teleflex has helped them grow personally and professionally, and how getting IVAN GERGEL, MD, MBA, MODERATOR: New Rhein Healthcare Investors JASON FREDERICK involved in the Life Sciences PA community is the key to a successful Representatives from new Member organizations joined the Ernst & Young membership. Represented new Member companies included: program to learn more about their Life Sciences PA membership and the many opportunities offered to Members.

ACHIEVENEXT GENE EDITING INSTITUTE - The program concluded with success stories from top CEOs in the CHRISTIANACARE industry who successfully executed exits in 2020. Attendees heard from: SAVIO GROUP ANALYTICS WOODRUFF SAWYER PATRICK DENTINGER JOSEPH TRUITT Absorption Systems, BioSpecifics Technologies Corp AZZUR GROUP A Pharmaron Company PINNAQL MODERATOR: BRUCE SHOOK RICH HUDOCK VEOLIA Vesper Medical The program’s second panel highlighted the success stories of colleagues and peers who led successful million- and billion- dollar acquisitions in 2020 and amidst the pandemic.

32 33 PROGRAMS IN Q4

HOLIDAY LUNCH PANEL December 17, 2020 | Hosted virtually

his year's Holiday Lunch Panel was designed to celebrate patients T and recent advocacy successes related to newborn screenings. The event featured a panel discussion focused on the wide-ranging benefits of expanded newborn screenings and recognized the importance of Pennsylvania's recently-passed Newborn Child Testing Act. Panelists included PA Senator John DiSanto (R-Dauphin & Perry Counties), sponsor of the Newborn Child Testing Act; Maria Kefalas of the Calliope Joy Foundation and Cure MLD, patient advocate; and Vincent Milano of Idera Pharmaceuticals, a leading developer of innovative therapies for rare diseases. Led by Amy O’Sullivan of Scope International USA, Panelists (clockwise from top left) Amy O’Sullivan, Vincent panelists discussed their efforts in relation to the Act and connected with Milano, Maria Kefalas and Senator John DiSanto discussed the many benefits of expanded newborn screening in Pennsylvania. attendees during networking sessions. PAGE INTENTIONALLY LEFT BLANK

After the panel, panelists and attendees continued the conversation in a post-event Zoom networking session.

34 35 PARTNERS

INTERNATIONAL PARTNERS REGIONAL PARTNERS

ASSOBIOTEC, THE ITALIAN ASSOCIATION FOR THE LITHUANIAN BIOTECHNOLOGY ASSOCIATION ALLEGHENY CONFERENCE ON COMMUNITY DEVELOPMENT LEHIGH VALLEY ECONOMIC DEVELOPMENT COUNCIL DEVELOPMENT OF BIOTECHNOLOGY ONE NUCLEUS BEN FRANKLIN TECHNOLOGY PARTNERS OF CENTRAL AND LIFE SCIENCES GREENHOUSE OF CENTRAL PENNSYLVANIA INDO-US SCIENCE & TECHNOLOGY FORUM PORTUGUESE PHARMACEUTICAL INDUSTRY ASSOCIATION NORTHERN PENNSYLVANIA LIFEX LABS KARNATAKA BIOTECHNOLOGY AND INFORMATION TECHNOLOGY SERVICES TAIWAN BIO INDUSTRY ORGANIZATION BEN FRANKLIN TECHNOLOGY PARTNERS OF NORTHEASTERN PENNSYLVANIA NEW JERSEY TECHNOLOGY COUNCIL MONTRÉAL INVIVO & QUÉBEC INTERNATIONAL BEN FRANKLIN TECHNOLOGY PARTNERS OF PENNSYLVANIA BIOTECHNOLOGY CENTER OF BUCKS SOUTHEASTERN PENNSYLVANIA COUNTY

BIOADVANCE PHILADELPHIA CONVENTION AND VISITORS BUREAU NATIONAL PARTNERS BIONJ PITTSBURGH LIFE SCIENCES GREENHOUSE

CHESTER COUNTY CHAMBER OF BUSINESS & INDUSTRY PITTSBURGH TECHNOLOGY COUNCIL

CHESTER COUNTY ECONOMIC DEVELOPMENT COUNCIL SELECT GREATER PHILADELPHIA

DELAWARE BIO THE CHAMBER OF COMMERCE FOR GREATER PHILADELPHIA

GREATER PHILADELPHIA ALLIANCE FOR CAPITAL AND THE MAIN LINE CHAMBER OF COMMERCE TECHNOLOGIES UNIVERSITY CITY SCIENCE CENTER

GREATER PITTSBURGH CHAMBER OF COMMERCE VALLEY FORGE TOURISM AND CONVENTION BOARD

HEALTHCARE INSTITUTE OF NEW JERSEY WE WORK FOR HEALTH PENNSYLVANIA

HERSHEY CENTER FOR APPLIED RESEARCH WORLD TRADE CENTER OF GREATER PHILADELPHIA

INNOVATION WORKS

36 37 MEMBERSHIP WELCOME 2020 NEW MEMBERS

n 2020, Life Sciences PA was pleased to welcome 59 new Members ADARE PHARMA SOLUTIONS HEALTHQUEST CAPITAL RX2 SOLUTIONS to the organization. While there have certainly been many positive I ADVANCED CLINICAL HEPATITIS B FOUNDATION SAVIO GROUP ANALYTICS/ SAVIO GROUP changes to the Life Sciences PA membership over the past 12 months, the year did not come without its fair share of challenges, COVID-19 AMBULATUS ROBOTICS JACKSON CROSS PARTNERS, LLC SENECA THERAPEUTICS, INC.

being the greatest. Following the outbreak of the COVID-19 pandemic, $12.7M APPIAN CORPORATION KYOWA KIRIN SIGNANT HEALTH many of our Member companies were in financial limbo. In order to SAVED IN 2020 BANCROFT CONSTRUCTION COMPANY LABCONNECT SOCIAL ASSURANCE MEDIA support our membership to our best ability, Life Sciences PA began a 5-month dues suspension from mid-March through mid-August. BI WORLDWIDE LAVA THERAPEUTICS B.V. SOLOMON PAGE This suspension allowed Members to refocus their financial resources BIOMARIN PHARMACEUTICAL, INC. LIFE SCIENCE CARES PHILADELPHIA TAIHO ONCOLOGY, INC. as needed, without worrying about the status of their membership. Life Sciences PA ended the year with 811 Member organizations BLACKFYNN, INC. LIFESCAN, INC. TOTAL PACKAGE PARTNERS

representing all sectors of the life sciences community: research BLUE SPARK TECHNOLOGIES LIVANOVA- TANDEMLIFE, CO. TRADECRAFT CLINICAL RESEARCH, LLC institutions, biotech, pharma, devices, diagnostics, investment, digital BRENTWOOD INDUSTRIES, INC. LUCASPYE BIO, LLC TREOVIR LLC health, contract research organizations, patient advocacy groups 811 and service providers. MEMBER COMPANIES CONTEMPORARY PUBLISHING GROUP EAST MEDIX ULTRATELLEGE USA CO. LTD. CORP

MERZ VEOLIA ES TECHNICAL SOLUTIONS, L.L.C. deeper look into the membership composition shows continued CORPORATE INTERIORS A strength in all sectors from the previous year. As the Life DISCOVERY SEARCH PARTNERS NEURALERT TECHNOLOGIES LLC VITARA BIOMEDICAL Sciences PA membership continues to evolve, this expanding network DOVA PHARMACEUTICALS NEURAPTIVE THERAPEUTICS, INC. VIVASC THERAPEUTICS, INC. provides even greater opportunity to facilitate strategic connections among members and to advocate for effective public policy. With DRUGSMITH CONSULTING NEXCLEAN VOLPE AND KOENIG input from our diverse membership, Life Sciences PA seeks to create 59 FIRSTLIGHT PHARMACEUTICALS PINNAQL INC. WOODRUFF SAWYER an environment to ensure the Commonwealth of Pennsylvania is NEW MEMBERS FONSECA BIOSCIENCES POCONO RABBIT FARM & LAB INC. X-VAX TECHNOLOGY, INC. considered the most attractive location in the United States for IN 2019 establishing and growing a life sciences organization. FUZEIT SOLUTIONS POLYCORE THERAPEUTICS ZYVERSA THERAPEUTICS

GENE EDITING INSTITUTE PREMIER FOCUS SOLUTIONS

CHRISTIANACARE PROXUS HR

GLOBAL TAX MANAGEMENT RAVEN BIOMATERIALS

38 39

MEMBERSHIP MEMBERSHIP GROWTH OVER TIME MEMBERSHIP BY SECTOR

1000 6% 6%

12% SERVICE 12% SERVICE FUNDING 3% FUNDING 3% ORGANIZATION 39% ORGANIZATION 39% 842 CRO 6% MEDICAL DEVICE 10% CRO 6% MEDICAL DEVICE 10% 800 817 811 39% 39% 842 PATIENT PATIENT 755 10% 2 019 ADVOCACY 6% PHARMA 12% 10% 811 ADVOCACY 6% PHARMA 12% 716 2020 DIGITAL HEALTH 1% RESEARCH / DIGITAL HEALTH 1% RESEARCH / 674 UNIVERSITY 6% UNIVERSITY 6% 651 3% 3% BIOTECH 17% BIOTECH 17% 604 600 17% 6% 17% 6% 547 6% 6%

504 1% 1%

432

400 378 346 CORE & ASSOCIATE MEMBERS

200

Core: Organizations involved in biotechnology or pharmaceutical research and development, drug discovery, medical device development and contract 2008 2009 2010 2 011 2012 2013 2 014 2015 2016 2 017 2018 2 019 2020 61% CORE 61% 2020 ASSOCIATE 39% research organizations involved in preclinical research.

39%

Associate: Businesses providing consulting and business services to the life sciences industry.

DIAMOND MEMBERS LEADERSHIP MEMBERS

ALMAC GROUP CONNER STRONG & BUCKELEW KPMG LLP TELEFLEX INCORPORATED

BALLARD SPAHR LLP DSM BIOMEDICAL LILLY USA, LLC TROUTMAN PEPPER

BAYER U.S. LLC LLP MORGAN LEWIS & BOCKIUS LLP WUXI ADVANCED THERAPIES

BRISTOL MYERS SQUIBB COMPANY ERNST & YOUNG, LLP PECO, AN EXELON COMPANY

CELERION, INC. HARMONY BIOSCIENCES TAKEDA PHARMACEUTICALS USA, INC.

40 41 MEMBERSHIP SAVING MILLIONS FOR MEMBERS PATIENT ADVOCACY GROUPS To best support our Members, Life Sciences PA consistently evaluates the services and offerings that are most beneficial. Life Sciences PA’s S.A.V.E. (Savings, Access, Value and Ease) Program is a powerful group purchasing program offering discounts on products and services to Life Sciences PA Members. This program enables Members to grow and expand their current operations, while saving capital and resources. Life Sciences PA Members saved more than $12.7 million in 2020 by utilizing ALEX'S LEMONADE STAND FOUNDATION GARRETT THE GRAND - BATTEN FIGHTER the S.A.V.E. Program. ALS ASSOCIATION GREATER PHILADELPHIA CHAPTER GBS/ CIDP FOUNDATION INTERNATIONAL In mid-November, Life Sciences PA announced the addition of Veolia as a S.A.V.E. provider. Earlier in 2020, results from a Member survey identified a need for waste ALZHEIMER'S ASSOCIATION - DELAWARE VALLEY CHAPTER HEPATITIS B FOUNDATION management and environmental compliance. To address this need, Life Sciences PA expanded the S.A.V.E. Program to include Veolia, an organization that provides AMERICAN ASSOCIATION FOR CANCER RESEARCH KIDNEYCAN environmental waste services through a network of 50 service centers and treatment, recovery and disposal facilities. AMERICAN CANCER SOCIETY LEUKEMIA & LYMPHOMA SOCIETY With our group of nine S.A.V.E. providers, Members can receive discounts on products and services ranging from office supplies and travel planning, to IT services and AMERICAN DIABETES ASSOCIATION LUPUS FOUNDATION OF AMERICA: PHILADELPHIA TRI-STATE lab supplies. Below is information about our growing S.A.V.E. program and a list of our providers. CHAPTER AMERICAN HEART ASSOCIATION NATIONAL ATAXIA FOUNDATION AMERICAN LIVER FOUNDATION 13 NATIONAL OSTEOPOROSIS FOUNDATION $12.7M AMERICAN LUNG ASSOCIATION OF THE MID-ATLANTIC MEMBER SAVINGS, NEPHCURE KIDNEY INTERNATIONAL FOUNDATION GROUP PURCHASING AMYLOIDOSIS FOUNDATION NORD 102 ARMORUP FOR LIFE $11.7M PA BREAST CANCER COALITION ARTHRITIS FOUNDATION (SOUTHEASTERN PA CHAPTER)

RARE GENOMICS INSTITUTE 10 CASTLEMAN DISEASE COLLABORATIVE NETWORK $9.7M SICK CELLS COMMUNITY LIVER ALLIANCE $8.4M SIMON'S HEART

CROHN'S & COLITIS FOUNDATION OF AMERICA ) 8 SOLDIERSTRONG CURING RETINAL BLINDNESS FOUNDATION $6.5M SUSAN G. KOMEN - PHILADELPHIA vings (in millions Sa DYSAUTONOMIA INTERNATIONAL 6 THE CALLIOPE JOY FOUNDATION EASTERN PA CHAPTER, NATIONAL HEMOPHILIA $5.2M FOUNDATION THE CONLEY CUSHING'S DISEASE FUND $4.5M

4 EMILY WHITEHEAD FOUNDATION THERAPEUTIC RESEARCH FOUNDATION, INC. EMILY'S ENTOURAGE UNITED MITOCHONDRIAL DISEASE FOUNDATION EPILEPSY FOUNDATION UPLIFTING ATHLETES 2 EVERYLIFE FOUNDATION FOR RARE DISEASES WESCOE FOUNDATION FOR PULMONARY FIBROSIS

FOR PETE'S SAKE CANCER RESPITE FOUNDATION WESTERN PA CHAPTER, NATIONAL HEMOPHILIA 0 2014 2015 2016 2017 2018 2 019 2020 FOUNDATION FRIEDREICH'S ATAXIA RESEARCH ALLIANCE

42 43 2020 BOARD OF DIRECTORS

MICHAEL BOZIK, M.D. Andrew Greenspan, M.D. David Payne, Ph.D. DSc Neal Walker, D.O. President & CEO Vice President Vice President President & CEO Knopp Biosciences LLC Immunology Medical Affairs Medicine Opportunities Research Aclaris Therapeutics Janssen Scientific Affairs, LLC GlaxoSmithKline

Erin Brubaker Vice President Corporate Development Brian K. Halak, Ph.D. Robert Radie Monte Wiltse Passage Bio Partner Chairman and Chief Executive Officer President & CEO Domain Associates Neuraptive Therapeutics, Inc Fujirebio Diagnostics

Bert Bruce Vice President Thomas Hess, CPA (Treasurer) Matthew Reber John Witkowski Global Commercial Development, Senior Vice President & CFO Partner President MEDICAL DEVICE & DIAGNOSTICS COMMITTEE Rare Disease Genomind 1315 Capital DSM Biomedical Pfizer Biopharmaceuticals Group Pfizer, Inc. BRUCE SHOOK THOMAS HESS CHRISTIAN MANDERS John Hubbard, Ph.D., FCP Julian Ritchey Bryan Wolf, M.D., Ph.D. Healthcare Strategic US Head Vaccine Executive Vice President NEIL CAMPBELL LIAM KELLY ERIC TEUTSCH Christopher Burns, Ph.D. Advisory Board Member Public Affairs and Advocacy & Chief Scientific Officer President & CEO Genstar Capital Sanofi Pasteur Children’s Hospital of Philadelphia ADAM DAKIN MARC MALANDRO ALAN WEST Venatorx Pharmaceuticals, Inc.

Stephen Jannetta Michael J. Ruggiero Stephen Yoder, M.D. Rachael Bushey Partner Senior Vice President Vice President Partner and Chair of the Morgan, Lewis & Bockius LLP Global Healthcare Policy Business Development Health Sciences Department & External Affairs Taiho Oncology, Inc. Troutman Pepper CSL Behring Liam Kelly President & CEO Neil Campbell, Ph.D. Teleflex Incorporated Kathleen Shay (Secretary) Executive Chairman Partner Mosaigen, LLC Duane Morris LLP THANK YOU TO OUR Mahmood Ladha GOVERNANCE COMMITTEES President & Head of Dova FORMER BOARD MEMBERS Christopher Cashman Dova Pharmaceuticals Bruce Shook FOR YOUR CONTRIBUTIONS. EXECUTIVE AUDIT NOMINATING Chairman President & Chief Executive Officer MBF Therapeutics Vesper Medical TERRI LEE TAYLOR (CHAIR) THOMAS HESS (CHAIR) KATHLEEN SHAY (CHAIR) David H. Ledbetter, Ph.D., FACMG ARMANDO ANIDO Executive Vice President STEPHEN TULLMAN JASON FREDERICK CHRISTOPHER MOLINEAUX Susan Dillon, Ph.D. & Chief Scientific Officer John Swartley, Ph.D. MATTHEW GANTZ President & CEO Geisinger Associate Vice Provost for MAXINE GOWEN KATHLEEN SHAY BRUCE SHOOK Aro Biotherapeutics Research & Managing Director, Penn Center for Innovation JOSEPH LA BARGE BRIAN HALAK TERRI LEE TAYLOR STEPHEN TULLMAN Bryant Lim University of Pennsylvania Brian Doerner Senior Vice President ADELE C. OLIVA THOMAS HESS STEPHEN TULLMAN TERRI LEE TAYLOR Partner General Counsel & Secretary Ballard Spahr LLP Idera Pharmaceuticals Terri Lee Taylor (Chairman) CHRISTOPHER MOLINEAUX EDMUND LYNCH Vice President ROBERT SMITH State Government Affairs & Policy BRUCE SHOOK CHRISTOPHER MOLINEAUX Evan Facher Christian Manders Merck & Co, Inc. JENNIFER STRONG Vice Chancellor for Innovation Chief Operating Officer KATHLEEN SHAY STEPHEN WEBSTER and Entrepreneurship and Promethean LifeSciences Director of the Innovation Institute Paul Testa JING YANG, PH.D. University of Pittsburgh Executive Vice President Peter Miller Operations/Supply Chain Chief Executive Officer Kyowa Kirin Jason Frederick Optinose Partner Strategic Growth Markets Eric Teutsch Ernst & Young LLP Christopher Molineaux (President) Board of Directors President & CEO and Senior Commercial Advisor Life Sciences Pennsylvania Cambridge Orthopaedic Labs Maxine Gowen, Ph.D. Director & CEO TamuroBio Inc. Rita Norton Stephen Tullman (Vice-Chairman) Senior Vice President Managing Partner Government Affairs & Public Policy NeXeption AmerisourceBergen Corporation

44 45 IN RECOGNITION OF OUR LSPA STAFF 2020

GENEROUS SPONSORS CHRISTOPHER P. ADVOCACY PROGRAMS COMMUNICATIONS MOLINEAUX KURT IMHOF MELISSA CALLUM STEPHANIE WEBSTER We are deeply appreciative of the following individuals for their generous support in bringing you the 2020 Annual Report. President & CEO Vice President, Director, Programs Manager, Communications [email protected] Policy and Public Affairs [email protected] [email protected] MATTHEW REBER JASON FREDERICK TERRI LEE TAYLOR STEPHEN YODER, M.D. 1315 Capital Ernst & Young Merck & Company, Inc. Taiho Oncology, Inc. 610-947-6800 ext. 203 [email protected] 610-947-6800 ext. 208 610-947-6800 ext. 217 610-947-6800 ext. 211 KAREN DELONE JILL HUBER KARA EVANS NEAL WALKER, D.O. MONTE WILTSE NEIL CAMPBELL, PH.D. MAXINE GOWEN, PH.D. Aclaris Therapeutics, Inc. Fujirebio Diagnostics Moisagen, LLC Tamuro Bio Senior Vice President & JENNIFER YOUNG Director, Programs Coordinator, Member & Chief Operating Officer Senior Director, [email protected] Program Communications [email protected] Policy & Public Affairs 412-584-7651 [email protected] RITA NORTON DAVID LEDBETTER, PH.D., FACMG STEPHEN JANNETTA LIAM KELLY 610-947-6800 ext. 210 [email protected] 610-947-6800 AmerisourceBergen Geisinger Morgan, Lewis,& Bockius LLP Teleflex Incorporated 412-584-7651 LAUREN BOYLE Programs Coordinator SUSAN DILLION, PH. D. THOMAS HESS STEPHEN TULLMAN BRYAN WOLF, M.D., PH.D. [email protected] ARO Therapeutics Genomind NeXeption The Children's Hospital of 610-947-6800 ext. 206 Philadelphia

BRIAN DOERNER DAVID PAYNE, PH.D., DSC PETER MILLER OPERATIONS MEMBERSHIP Ballard Spahr LLP GlaxoSmithKline Optinose JOHN SWARTLEY, PH.D. BETTY PIKE LOIS STEPHENS University of Pennsylvania Accountant Membership Manager MICHAEL RUGGIERO BRYANT LIM RACHAEL BUSHEY [email protected] [email protected] 610-947-6800 ext. 207 610-947-6800 ext. 209 CSL Behring Idera Pharmaceuticals, Inc. Troutman Pepper EVAN FACHER, PH.D. University of Pittsburgh JAMIE BUBECK NICOLE MEROLLA BRIAN HALAK, PH.D. ANDREW GREENSPAN, M.D. BERT BRUCE Accountant Membership & Programs Domain Associates Janssen Biotech Pfizer, Inc. CHRISTOPHER BURNS, PH.D. Venatorx Pharmaceuticals, Inc. [email protected] Coordinator 610-947-6800 ext. 218 [email protected] MAHMOOD LADHA MICHAEL BOZIK, M.D. CHRISTIAN MANDERS 610-947-6800 ext. 204 Dova Pharmaceuticals Knopp Biosciences Promethean LifeSciences BRUCE SHOOK Vesper Medical, Inc. JOHN WITKOWSKi PAUL TESTA JULIAN RITCHEY DSM Biomedical Kyowa Kirin USA Holdings Sanofi Pasteur

KATHLEEN SHAY CHRISTOPHER CASHMAN JOHN HUBBARD, PH.D., FCP Duane Morris LLP MBF Therapeutics Signant Health

46 47 CONNECT. ADVOCATE. ADVANCE. LIFE SCIENCES PENNSYLVANIA

WWW.LIFESCIENCESPA.ORG

48 49 650 EAST SWEDESFORD ROAD SUITE 190 WAYNE, PA 19087

WWW.LIFESCIENCESPA.ORG